UTIs Diagnosed with Genetic Analysis of Cell-Free DNA
By LabMedica International staff writers Posted on 03 Jul 2018 |
Image: Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white blood cells in urinary microscopy. These changes are indicative of a urinary tract infection (Photo courtesy of Wikimedia Commons).
Genetic analysis of cell-free DNA (cfDNA) in urine samples reveals valuable information, which enables comprehensive monitoring of host and pathogen dynamics in bacterial and viral urinary tract infections.
Investigators at Cornell University (Ithaca, NY, USA) isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing.
The analysis revealed that urinary cfDNA was highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. These different layers of information were accessible from a single assay and individually agreed with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. Furthermore, cfDNA revealed the frequent occurrence of diseases that remained undiagnosed with conventional diagnostic protocols.
“We found that we could deduce the fraction of the bacterial population that is growing, by carefully looking at the places in the genome where the cell-free DNA was derived from” said senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University. "Metagenomic analysis of the cell-free DNA can also be used to infer which antimicrobial drugs may work best against a particular infection."
The paper describing genetic analysis of cell-free DNA in urine specimens was published in the June 20, 2018, online edition of the journal Nature Communications.
Related Links:
Cornell University
Investigators at Cornell University (Ithaca, NY, USA) isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing.
The analysis revealed that urinary cfDNA was highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. These different layers of information were accessible from a single assay and individually agreed with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. Furthermore, cfDNA revealed the frequent occurrence of diseases that remained undiagnosed with conventional diagnostic protocols.
“We found that we could deduce the fraction of the bacterial population that is growing, by carefully looking at the places in the genome where the cell-free DNA was derived from” said senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University. "Metagenomic analysis of the cell-free DNA can also be used to infer which antimicrobial drugs may work best against a particular infection."
The paper describing genetic analysis of cell-free DNA in urine specimens was published in the June 20, 2018, online edition of the journal Nature Communications.
Related Links:
Cornell University
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear